Stock of the Day

July 29, 2024

Edwards Lifesciences (EW)

$79.31
-$1.85 (-2.3%)
Market Cap: $46.52B

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Edwards Lifesciences Bull Case

Here are some ways that investors could benefit from investing in Edwards Lifesciences Co.:

  • The stock has recently seen a price target increase to $95.00, indicating positive analyst sentiment and potential for growth.
  • Edwards Lifesciences Co. has a strong market capitalization of approximately $46.88 billion, suggesting stability and investor confidence.
  • The current stock price is around $79.92, which is near its 52-week high of $83.00, reflecting strong performance in the market.
  • Analysts have given the stock a consensus rating of "Moderate Buy," with a significant number of buy ratings, indicating overall positive outlook.
  • The company has a low debt-to-equity ratio of 0.06, which suggests financial stability and lower risk for investors.

Edwards Lifesciences Bear Case

Investors should be bearish about investing in Edwards Lifesciences Co. for these reasons:

  • Some analysts have issued hold ratings, indicating uncertainty about the stock's short-term performance.
  • There has been a recent decrease in target prices from some analysts, which may suggest potential challenges ahead.
  • The stock has a price-to-earnings (P/E) ratio of 11.50, which, while not excessively high, may indicate limited growth potential compared to higher-growth sectors.
  • Market volatility could impact the stock's performance, as indicated by its beta of 1.11, suggesting it may be more volatile than the market average.
  • Despite recent positive developments, the stock has experienced fluctuations, with a 1-year low of $59.41, indicating potential risks for investors.
← Previous Stock of the DayNext Stock of the Day →

Recent News